Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
December 19 2023 - 8:30AM
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical
biopharmaceutical company focused on the discovery, development and
commercialization of drugs for the treatment of cancer, today
announced a new licensing agreement with the Wisconsin Alumni
Research Foundation (WARF) for intellectual property that was the
result of collaborative research conducted at the University of
Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers.
Under the terms of the agreement, Cellectar has
an exclusive license to develop and commercialize iopofosine in
various pediatric solid cancers, such as high-grade glioma,
neuroblastoma and sarcoma.
“This licensing agreement further strengthens
our iopofosine I 131 patent portfolio and our industry leading
position in radiopharmaceutical patent grants and applications. It
also expands our long-standing relationship with the University of
Wisconsin. WARF, the intellectual property management arm of the
UW, is highly respected for its longstanding history of
successfully protecting intellectual property associated with its
license agreements.” said James Caruso, president and CEO of
Cellectar. “Based on the encouraging performance of iopofosine in
our pediatric Phase 1a study, we were awarded a $2 million NCI
grant to further evaluate the activity of iopofosine in pediatric
high-grade gliomas with anticipation of first patient enrollment in
the near term.”
About the Wisconsin Alumni Research
Foundation
WARF was created by University of Wisconsin
visionaries to enable the university’s research to solve the
world’s problems. WARF supports scientific research within the
UW-Madison community by providing financial support, actively
managing assets and moving innovations to the marketplace for a
financial return and global impact. As the designated patenting and
licensing organization, WARF has helped advance transformative
discoveries to market for the past century.
About Cellectar Biosciences,
Inc.
Cellectar Biosciences is focused on the
discovery and development of drugs for the treatment of cancer. The
company is developing proprietary drugs independently and through
research and development collaborations. The company’s core
objective is to leverage its proprietary Phospholipid Drug
Conjugate™ (PDC) delivery platform to develop PDCs that
specifically target cancer cells to deliver improved efficacy and
better safety with fewer off-target effects. The company’s PDC
platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and develops
PDCs independently and through research and development
collaborations.
The company’s product pipeline includes
iopofosine I 131, a small-molecule PDC designed to provide targeted
delivery of iodine-131 (radioisotope), proprietary preclinical PDC
chemotherapeutic programs and multiple partnered PDC assets. The
company is currently investigating iopofosine in a global,
open-label, pivotal expansion cohort in relapsed or refractory WM
patients who have received at least two prior lines of therapy,
including those who have failed or had a suboptimal response to
Bruton tyrosine kinase inhibitors. The WM cohort will enroll up to
50 patients to evaluate the efficacy and safety of iopofosine for
marketing approval. The company is also evaluating iopofosine in
highly refractory multiple myeloma patients in its Phase 2 CLOVER-1
study and relapsed/refractory pediatric cancer patients with brain
tumors in the Phase 1 CLOVER-2 study.
The Phase 1 pediatric study is an open-label,
dose finding study to evaluate the activity and safety of different
dosages and dosing regimens of iopofosine in children and
adolescents with relapsed or refractory brain tumors. The study is
being conducted in up to fifteen leading pediatric cancer centers
in North America.
The company has established exclusivity on a
broad U.S. and international intellectual property rights portfolio
around its proprietary cancer-targeting PLE technology platform,
including iopofosine and its PDC programs.
In addition to the company’s exclusivity to
iopofosine and its phospholipid ethers conjugated to small
molecules, peptides, and oligos, the company now has non-exclusive
rights to the use of the phospholipid ether platform when
conjugating with a chelator to bind select metal radioisotopes.
For more information, please visit
www.cellectar.com and www.wmclinicaltrial.com or join the
conversation by liking and following us on the company’s social
media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement
Disclaimer
This news release contains forward-looking
statements. You can identify these statements by our use of words
such as "may," "expect," "believe," "anticipate," "intend,"
"could," "estimate," "continue," "plans," or their negatives or
cognates. These statements are only estimates and predictions and
are subject to known and unknown risks and uncertainties that may
cause actual future experience and results to differ materially
from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our
expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might
cause such a material difference include, among others,
uncertainties related to the ability to raise additional capital,
uncertainties related to the disruptions at our sole source
supplier of iopofosine, the ability to attract and retain partners
for our technologies, the identification of lead compounds, the
successful preclinical development thereof, patient enrollment and
the completion of clinical studies, the FDA review process and
other government regulation, our ability to maintain orphan drug
designation in the United States for iopofosine, the volatile
market for priority review vouchers, our pharmaceutical
collaborators' ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies,
product pricing and third-party reimbursement. A complete
description of risks and uncertainties related to our business is
contained in our periodic reports filed with the Securities and
Exchange Commission including our Form 10-K for the year ended
December 31, 2022, and our Form 10-Q for the quarter ended
September 30, 2023. These forward-looking statements are made only
as of the date hereof, and we disclaim any obligation to update any
such forward-looking statements.
Contacts
Media:Claire LaCagninaBliss Bio
Health315-765-1462clacagnina@blissbiohealth.com
Investors:
Monique
Kosse646-258-5791investors@cellectar.com
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2023 to Apr 2024